Fieldview Capital Management LLC Purchases Shares of 1,366 Axon Enterprise, Inc $AXON

Fieldview Capital Management LLC acquired a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the 4th quarter, Holdings Channel.com reports. The fund acquired 1,366 shares of the biotechnology company’s stock, valued at approximately $776,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Evergreen Capital Management LLC boosted its holdings in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. Wealth Alliance LLC boosted its holdings in shares of Axon Enterprise by 3.2% during the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 18 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Axon Enterprise by 0.5% during the 3rd quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock valued at $2,848,000 after purchasing an additional 19 shares during the last quarter. CWA Asset Management Group LLC boosted its holdings in shares of Axon Enterprise by 5.2% during the 4th quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 19 shares during the last quarter. Finally, Synergy Financial Group LTD boosted its holdings in shares of Axon Enterprise by 1.4% during the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after purchasing an additional 19 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a report on Thursday, May 7th. Barclays dropped their price objective on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a report on Friday, May 8th. TD Cowen dropped their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Piper Sandler reissued an “overweight” rating and set a $674.00 price objective on shares of Axon Enterprise in a report on Monday. Finally, Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $443.21 on Tuesday. The firm has a market cap of $35.72 billion, a PE ratio of 178.00, a price-to-earnings-growth ratio of 8.03 and a beta of 1.45. The firm’s 50 day simple moving average is $410.95 and its 200-day simple moving average is $488.34. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period last year, the company posted $1.47 earnings per share. As a group, equities analysts predict that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In other news, CRO Cameron Brooks sold 1,242 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the transaction, the executive directly owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the transaction, the insider directly owned 34,024 shares in the company, valued at approximately $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 38,989 shares of company stock valued at $19,090,083. 4.20% of the stock is owned by corporate insiders.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.